| Description | ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV). |
| In vitro | 在 HepDES19 细胞中，ccc_R08（0.3, 1.0, 3.2, 10, 32 µM；5天）能够降低 cccDNA、无蛋白质的 RC-DNA 和双链线性 DNA（DL-DNA）的水平[1]。 |
| In vivo | 在HBV循环小鼠模型中，ccc_R08（20 mg/kg；口服；每天两次，连续2周）能够导致HBV循环小鼠肝脏中cccDNA的清除[1]。 |
| molecular weight | 414.84 |
| Molecular formula | C22H19ClO6 |
| CAS | 2919019-72-8 |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 80 mg/mL (192.85 mM), Sonication is recommended. |
| References | 1. Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. 2. Ligat G, et al. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatol Rep. 2020 Sep;19(3):235-244. |